Early aggressive macrovascular disease and type 1 diabetes mellitus without chronic complications: a case report

BMC Research Notes

Marília Brito Gomes¹  Alessandra Saldanha de Mattos Matheus¹ 

[1] Diabetes Unit, State University of Rio de Janeiro, Rio de Janeiro, Brazil

关键词: Cardiovascular risk;    Macrovascular complications;    Coronary artery disease;    Type 1;    Diabetes mellitus;   

Others  :  1142508
DOI  :  10.1186/1756-0500-6-222

 received in 2012-07-16, accepted in 2013-04-24,  发布年份 2013

【 摘 要 】

Background

Type 1 diabetes (T1DM) is considered to be one of the most significant risk factors for the development of coronary artery disease (CAD). However, the specific risk predictor models for T1DM are subject to many limitations.

Case presentation

We report the case of a 42-year-old Caucasian woman presenting with T1DM for 26 years. During her chronic hyperglycemic evolution (mean of HbA1c > 3 percentage points above the superior limit) without microvascular complications, this patient presented with early and aggressive coronary artery disease, despite the lack of classical risk factors for CAD

Conclusions

The rapidly progressive macrovascular disease observed in this case demonstrates the different degrees of aggressiveness and unpredictable clinical evolution observed in some cases. It also confirms the need for a multi-factorial, early and optimized clinical management regime.

【 授权许可】

   
2013 Matheus and Gomes; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

Figure 5.

Figure 6.

Figure 7.

Figure 8.

【 参考文献 】

• [1]Lehto S, et al.: Poor glycemic control predicts coronary heart disease events in patients with type 1 diabetes without nephropathy. Arterioscler Thromb Vasc Biol 1999, 19(4):1014-1019.
• [2]Zgibor JC, et al.: Deficiencies of cardiovascular risk prediction models for type 1 diabetes. Diabetes Care 2006, 29:1860-1865.
• [3]Haffner SM, Lehto S, Rönnemaa T, Pyörälä K, Laakso M: Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 1998, 339(4):229-234.
• [4]Yusuf S, Hawken S, Ôunpuu S, Dans T, Avezum A, Lanas F, et al.: Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet 2004, 364:937-952.
• [5]Piegas LS, Avezum A, Pereira JCR, Rossi Neto JM, Hoepfner C, Farran JA, AFIRMAR study investigators, et al.: Risk factors for myocardial infarction in Brazil. Am Heart J 2003, 146:331-338.
• [6]Orchard TJ, et al.: Type 1 diabetes and coronary artery disease. Diabetes Care 2006, 29(11):2528-2538.
• [7]Dabelea , et al.: Effect of type 1 diabetes on the gender difference in coronary artery calcification: a role for insulin resistance? the coronary artery calcification in type 1 diabetes (CACTI) study. Diabetes 2003, 52:2833-2839.
• [8]Matheus ASM, Cobas RA, Gomes MB: Dyslipidemias in type 1 diabetes: a current approach. Arq Bras Endocrinol Metab 2008, 52(2):334-339.
• [9]Nathan DM, Cleary PA, Backlund JY, et al.: The diabetes control and complications trial/epidemiology of diabetes interventions and complications (DCCT/EDIC) study research group. Intensive diabetes treatment and CVD in patients with type 1 diabetes. N Engl J Med 2005, 353:2643-2653.
• [10]Dorman J, Tajima N, LaPorte R, Becker D, Cruickshanks K, Wagener D, Orchard T, Drash A: The Pittsburgh insulin-dependent diabetes mellitus (IDDM) morbidity and mortality study: case control analyses of risk factors for mortality. Diabetes Care 1985, 8:54-60.
• [11]DiaComp Investigators: A multinational comparison of complications assessment in type 1 diabetes. The DiaMond substudy of complications (DiaComp) level 2. Diabetes Care 2004, 27:1610-1617. 7
• [12]Kolvisto VA, Stevens LK, Mattock M, Ebeling P, Muggeo M, Stephenson J, Idzior Walus B, The EURODIAB IDDM Complications Study Group: Cardiovascular disease and its risk factors in IDDM in Europe. Diabetes Care 1996, 19:689-697.
• [13]Wajchenberg BL, Rassi N, Coutinho A, FeitosaI R, Lerário AC, Betti RTB: Cardiovascular disease in type 1 diabetes mellitus. Arq Bras Endocrinol Metab 2008, 52:387-397. 2
• [14]Deckert T, Feldt-Rasmussen B, Borch-Johnsen K, Jensen T, Kofoed-Enevoldsen A: Albuminuria reflects widespread vascular damage. The steno hypothesis. Diabetologia 1989, 32:219-226.
• [15]Stehouwer CD, Fischer HR, van Kuijk AW, Polak BC, Donker AJ: Endothelial dysfunction precedes development of microalbuminuria in IDDM. Diabetes 1995, 44:561-564.
• [16]Gomes MB, et al.: Plasma PAF-acetylhydrolase activity, inflammatory markers and susceptibility of LDL to in vitro oxidation in patients with type 1 diabetes mellitus. Diabetes Res Clin Pract 2009, 85(1):61-68.
• [17]Beckman JA, Creager MA, Libby P: Diabetes and atherosclerosis — Epidemiology, pathophysiology and management. JAMA 2002, 287:2570-2581.
• [18]Carter AM: Inflammation, thrombosis and acute coronary syndromes. Diabetes Vasc Dis Res 2005, 2:113-121.
• [19]Reis JS, et al.: Oxidative stress: a review on metabolic signaling in type 1 diabetes. Arq Bras Endocrinol Metab 2008, 52/7:1096-1105.
• [20]Braga JR, et al.: The impact of diabetes mellitus on the mortality of acute coronary syndromes. Arq Bras Endocrinol Metab 2007, 51(2):275-280.
• [21]Franklin K, Goldberg RJ, Spencer F, Klein W, Budaj A, Brieger D: Implications of diabetes in patients with acute coronary syndromes. The global registry of acute coronary events. Arch Intern Med 2004, 64:1457-1463.
• [22]Costacou T, Ferrell RE, Orchard TJ: Haptoglobin genotype: a determinant of cardiovascular complication risk in type 1 diabetes. Diabetes 2008, 57:1702-1706.
• [23]Vardi M, Blum S, Levy AP: Haptoglobin genotype and cardiovascular outcomes in diabetes mellitus- natural history of the disease and the effect of vitamin E treatment. Meta-analysis of the medical literature. Eur J Intern Med 2001, 23(7):628-632.
• [24]Söderlund J, Forsblom C, Ilonen J, Thorn LM, Wadén J, Parkkonen M, Groop PH, FinnDiane Study Group: HLA class II is a factor in cardiovascular morbidity and mortality rates in patients with type 1 diabetes. Diabetologia 2012, 55(11):2963-2969.
• [25]Natarajan S, et al.: Sex differences in risk for coronary heart disease mortality associated with diabetes and established coronary heart disease. Arch Intern Med 2003, 163:1735-1740.
• [26]Laing SP, Swerdlow AJ, Slater SD, Burden AC, Morris A, Waugh NR, et al.: Mortality from heart disease in a cohort of 23,000 patients with insulin-treated diabetes. Diabetologia 2003, 46:760-765.
• [27]Cobas RA, et al.: Type 1 diabetic patients evolution to hypertension. Arq Bras Endocrinol Metab 2008, 52(4):628-634.
• [28]Mosca L, Appel LJ, Benjamin EJ, Berra K, Chandra-Strobos N, Fabunmi RP, et al.: Evidence-based guidelines for cardiovascular disease prevention in women. American heart association scientific statement. Arteriosclerosis Thromb Vasc Biol 2004, 24:e29-e50.
• [29]Douglas PS, Ginsburg GS: The evaluation of chest pain in women. N Engl J Med 1996, 334:1311-1315.
• [30]Mosca L, Grundy SM, Judelson D, King K, Limacher M, Oparil S, et al.: Guide to preventive cardiology for women. AHA/ACC scientific statement consensus panel statement. Circulation 1999, 99:2480-2484.
• [31]Mieres JH, Shaw LJ, Hendel RC, Miller DD, Bonow RO, Berman DS, et al.: American society of nuclear cardiology consensus statement: task force on women and coronary artery disease – the role of myocardial perfusion imaging in the clinical evaluation of coronary artery disease in women. J Nucl Cardiol 2003, 10:95-101.
• [32]Kannel WB: The Framingham study: historical insight on the impact of cardiovascular risk factors in men versus women. J Gend Specif Med 2002, 5:27-37.
• [33]Smanio P: Cardiovascular disease in diabetic women without cardiac symptoms. Arq Bras Endocrinol Metab 2007, 51(2):305-311.